Compare efficacy and safety data for new and emerging treatments for second-line ES-SCLC, as well for immunotherapies approved in subsequent lines
|
|
|
|
|
|
Develop a plan of action for selecting appropriate treatment options for ES-SCLC patients who evidence disease progression during or after first-line chemotherapy
|
|
|
|
|
|